Sanofi hints at 'class ef­fec­t' for mR­NA flu shot as it un­veils vac­cine R&D plans dri­ven by $3.2B deal

French drug­mak­er Sanofi show­cased its vac­cine fran­chise, part of a promise made two years ago to over­haul what the com­pa­ny at the time ac­knowl­edged was a lag­ging part of its busi­ness.

Ahead of an event in Lon­don on Thurs­day, the com­pa­ny pre­viewed new da­ta from a dozen vac­cine prod­ucts in de­vel­op­ment, in­clud­ing two mR­NA-based flu shots, RSV prod­ucts, a pneu­mo­coc­cal vac­cine, vac­cines for menin­gi­tis B and chlamy­dia, and a ther­a­peu­tic ac­ne vac­cine. Two of those — an RSV vac­cine and a pneu­mo­coc­cal vac­cine — are slat­ed to en­ter Phase III in the first half of 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER